[Telomerases: transformation trial!].
Lavelle
F
F
D000409:Alanine / Q000235:genetics; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001224:Aspartic Acid / Q000235:genetics; D020134:Catalytic Domain; D002455:Cell Division / Q000187:drug effects; D004268:DNA-Binding Proteins; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007532:Isoleucine / Q000235:genetics; D009369:Neoplasms / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control; D012313:RNA; D019098:Telomerase / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000627:therapeutic use; D014170:Transformation, Genetic / Q000235:genetics; D014407:Tumor Cells, Cultured; D014633:Valine / Q000235:genetics
D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D004791:Enzyme Inhibitors; C422952:telomerase RNA; D007532:Isoleucine; D001224:Aspartic Acid; D012313:RNA; D019098:Telomerase; D014633:Valine; D000409:Alanine